Coherus Bio (CHRS) Stock Price, Quote & News

Company Profile

Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin 27. It also develops CHS-114, an investigat...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 649 3530

Website: www.coherus.com

Address:

333 Twin Dolphin Drive, Suite 600, Redwood City, United States

Zackmax99 Feb. 23 at 7:22 PM

$CHRS Anyone seen anything on when earns will be? I found nothing on the website?

3 · Reply

MiamiGent Feb. 23 at 4:27 PM

$CHRS CHRS Back in for a 10% position at 1.61. Very ginger about it. If the US bombs Iran, the market could do anything, including tank. But an Offering just closed and usually heads up after that. An option for 4.3M additional shares likely keeping it soggy for now. 1.60 available at the moment. Do your own DD.

2 · Reply

BigDaddyCapital Feb. 23 at 4:17 PM

$CHRS massive order for 252k shares

0 · Reply

Grandgustav Feb. 23 at 3:27 PM

$CHRS upcoming investor conferences https://investors.coherus.com/news-releases/news-release-details/coherus-oncology-participate-upcoming-investor-conferences-1

0 · Reply

Grandgustav Feb. 23 at 1:42 PM

$CHRS Denny has news for us this week.

0 · Reply

HansDampf1 Feb. 23 at 12:35 PM

$CHRS "Merck to create separate cancer business to offset Keytruda patent loss, WSJ reports" https://finance.yahoo.com/news/merck-create-separate-cancer-business-112250919.html Would Coherus be a perfect base for this undertaking?

1 · Reply

BillionerOfKing Feb. 23 at 10:24 AM

$CHRS Current Stock Price: $1.64 Contracts to trade: $1.5 CHRS Mar 20 2026 Call Entry: $0.34 Exit: $0.53 ROI: 56% Hold ~22 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

Samishere Feb. 22 at 3:25 PM

$CHRS Dooopppp,, They did NOT ban tariffs- They did not strike down tariffs- they said the USE OF the emergency powers act rather than other tariff laws exceeded Presidential authority. They will just use other tariff laws to accomplish the same objective - a level playing field for international trade.

1 · Reply

cdlawton07 Feb. 20 at 9:50 PM

$CHRS I will suck Denny’s D if this goes to $10.

7 · Reply

Jack_Nicholson_Truth Feb. 20 at 5:02 PM

$CHRS good pt! For a micro cap like us, even 300-500k savings is huge for tori. Tori still not approved for esophageal in the us when it's approved in Europe and China. This has to be a priority as well.

0 · Reply

Coherus Oncology to Participate in Upcoming Investor Conferences

Feb 17, 2026, 4:11 PM EST - 6 days ago

Coherus Oncology, Inc. Announces Closing of Public Offering of Common Stock

Feb 12, 2026, 9:18 PM EST - 11 days ago

Coherus Oncology, Inc. Announces Pricing of Public Offering of Common Stock

Jan 13, 2026, 4:16 PM EST - 5 weeks ago

Coherus Oncology, Inc. (CHRS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 6, 2026, 9:30 AM EST - 6 weeks ago

Coherus Management to Present at the 44th Annual J.P. Morgan Healthcare Conference

Jan 5, 2026, 9:30 AM EST - 7 weeks ago

Coherus Oncology Announces Publication in Molecular Cancer Therapeutics Highlighting the Strong Pharmacology of Investigational CCR8 Antibody Tagmokitug (CHS-114)

Dec 23, 2025, 11:06 AM EST - 2 months ago

Coherus Oncology: A Two-Pronged March With Mid-2026 Implications

Dec 8, 2025, 8:30 AM EST - 2 months ago

Coherus Announces Six-Year JUPITER-02 Follow-up Results Showing LOQTORZI® plus Chemotherapy Nearly Doubles Median Overall Survival in Nasopharyngeal Carcinoma

Nov 10, 2025, 5:01 PM EST - 3 months ago

Coherus Oncology, Inc. (CHRS) Presents at UBS Global Healthcare Conference 2025 Transcript

Nov 7, 2025, 5:56 PM EST - 3 months ago

Coherus Oncology, Inc. (CHRS) Q3 2025 Earnings Call Transcript

Nov 7, 2025, 9:00 AM EST - 3 months ago

Coherus Oncology Presents at SITC Clinical Multiomic Biomarker Data for CHS-114, a Highly Selective anti-CCR8 Cytolytic Antibody

Nov 6, 2025, 4:14 PM EST - 3 months ago

Coherus Oncology Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 6, 2025, 1:54 PM EST - 3 months ago

Arvind Sood joins Coherus Oncology as Chief Strategy and Corporate Affairs Officer

Oct 30, 2025, 8:30 AM EDT - 4 months ago

Coherus Oncology to Report Third Quarter 2025 Financial Results on November 6, 2025

Oct 10, 2025, 4:32 AM EDT - 4 months ago

4 Biotechnology Stocks Lead Momentum Gains Amid Strong Technicals

ALDX ALEC BDTX

Oct 3, 2025, 9:05 AM EDT - 5 months ago

Coherus Oncology Announces Poster Presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Oct 1, 2025, 5:02 PM EDT - 5 months ago

Coherus Oncology, Inc. (CHRS) Presents at UBS Virtual Oncology Day Transcript

Oct 1, 2025, 10:43 AM EDT - 5 months ago

Coherus Oncology: Five Readouts Or More Possible In 2026

Aug 25, 2025, 4:55 PM EDT - 6 months ago

Coherus Oncology: On The Shaping Up

Aug 9, 2025, 11:35 AM EDT - 7 months ago

Coherus Oncology, Inc. (CHRS) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 4:41 PM EDT - 7 months ago

Coherus Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 31, 2025, 4:45 PM EDT - 7 months ago

Coherus Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025

May 12, 2025, 10:46 PM EDT - 10 months ago

Coherus BioSciences, Inc. (CHRS) Q1 2025 Earnings Call Transcript

May 12, 2025, 4:15 PM EDT - 10 months ago

Coherus BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update

May 5, 2025, 4:01 PM EDT - 10 months ago

Coherus to Report First Quarter 2025 Financial Results on May 12, 2025

May 1, 2025, 5:04 PM EDT - 10 months ago

Coherus to Participate in Upcoming Investor Conferences

Apr 28, 2025, 10:10 AM EDT - 10 months ago

Coherus Presents Promising Early Clinical Data from Phase 1 Dose Expansion Study of CHS-114 in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma at AACR 2025

Apr 17, 2025, 5:53 AM EDT - 11 months ago

Coherus BioSciences: Cleaning The Balance Sheet And Developing New Drugs

Apr 14, 2025, 8:00 AM EDT - 11 months ago

Coherus Completes Strategic Transformation with Successful Divestiture of UDENYCA® Franchise

Mar 25, 2025, 4:30 PM EDT - 11 months ago

Coherus to Present Data from a Phase 1 Dose Expansion Study of CHS-114, a Cytolytic Antibody Targeting Chemokine Receptor 8 (CCR8), at the 2025 American Association for Cancer Research (AACR) Annual Meeting

Mar 10, 2025, 8:52 PM EDT - 1 year ago

Coherus BioSciences, Inc. (CHRS) Q4 2024 Earnings Call Transcript

Mar 10, 2025, 4:12 PM EDT - 1 year ago

Coherus BioSciences Reports Fourth Quarter, Full Year 2024 Financial Results and Provides Business Update

Mar 3, 2025, 8:30 AM EST - 1 year ago

Coherus to Report Fourth Quarter and Full Year 2024 Financial Results on March 10, 2025

Feb 24, 2025, 9:08 AM EST - 1 year ago

Coherus Management to Participate at the 45th Annual TD Cowen Health Care Conference

Dec 18, 2024, 8:30 AM EST - 1 year ago

Coherus to Present Final Phase 2 Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025

Dec 16, 2024, 6:08 PM EST - 1 year ago

Coherus BioSciences: Shedding Pegfilgrastim To Fuel Ongoing Development

Dec 3, 2024, 9:34 AM EST - 1 year ago

Why Is Coherus BioSciences Stock Trading Higher On Tuesday?

Nov 27, 2024, 4:01 PM EST - 1 year ago

Coherus Management to Participate in the 2024 Citi Global Healthcare Conference

Nov 6, 2024, 11:09 PM EST - 1 year ago

Coherus BioSciences, Inc. (CHRS) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 4:01 PM EST - 1 year ago

Coherus BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update

Oct 30, 2024, 4:20 PM EDT - 1 year ago

Coherus to Report Third Quarter 2024 Financial Results on November 6, 2024

Aug 13, 2024, 10:01 AM EDT - 1 year ago

Evaluating Coherus BioSciences: Udenyca's Success And Loqtorzi's Prospects

Aug 9, 2024, 6:08 PM EDT - 1 year ago

Coherus BioSciences, Inc. (CHRS) Q2 2024 Earnings Call Transcript

Aug 1, 2024, 9:00 AM EDT - 1 year ago

Coherus to Report Second Quarter 2024 Financial Results on August 8, 2024

Jun 27, 2024, 8:26 AM EDT - 1 year ago

Coherus BioSciences Announces Divestiture of YUSIMRY (adalimumab-aqvh) in a $40 Million Upfront All Cash Transaction

May 31, 2024, 12:04 PM EDT - 1 year ago

Coherus BioSciences: CHS-114 Comes Into View At ASCO, Drug Launches Underway

May 30, 2024, 9:00 AM EDT - 1 year ago

Coherus Management to Present at the 2024 Jefferies Global Healthcare Conference

May 23, 2024, 5:51 PM EDT - 1 year ago

Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

May 23, 2024, 9:00 AM EDT - 1 year ago

Coherus Management to Present at the TD Cowen 5th Annual Oncology Innovation Virtual Summit: Insights for ASCO & EHA

May 10, 2024, 12:07 AM EDT - 1 year ago

Coherus BioSciences, Inc. (CHRS) Q1 2024 Earnings Call Transcript

Zackmax99 Feb. 23 at 7:22 PM

$CHRS Anyone seen anything on when earns will be? I found nothing on the website?

3 · Reply

MiamiGent Feb. 23 at 4:27 PM

2 · Reply

BigDaddyCapital Feb. 23 at 4:17 PM

$CHRS massive order for 252k shares

0 · Reply

Grandgustav Feb. 23 at 3:27 PM

$CHRS upcoming investor conferences https://investors.coherus.com/news-releases/news-release-details/coherus-oncology-participate-upcoming-investor-conferences-1

0 · Reply

Grandgustav Feb. 23 at 1:42 PM

$CHRS Denny has news for us this week.

0 · Reply

HansDampf1 Feb. 23 at 12:35 PM

1 · Reply

BillionerOfKing Feb. 23 at 10:24 AM

0 · Reply

Samishere Feb. 22 at 3:25 PM

1 · Reply

cdlawton07 Feb. 20 at 9:50 PM

$CHRS I will suck Denny’s D if this goes to $10.

7 · Reply

Jack_Nicholson_Truth Feb. 20 at 5:02 PM

0 · Reply

Grandgustav Feb. 20 at 4:53 PM

$CHRS wonder if we'll get any rebates from Trump's tariffs being struck down. Might not amount to much, but every penny counts

1 · Reply

DeltaNinety Feb. 20 at 2:57 PM

Liking this little guy stock $CHRS. Has potential to head back to fill it's gap and head back towards $2.50+

1 · Reply

Jack_Nicholson_Truth Feb. 19 at 8:19 PM

$CHRS it is possible to skip P3 but data would have to be overwhelming. If they get the same cr rate of 15% with higher orr, it is possible. It would need to be rvmd good to skip P3.

4 · Reply

Fomoninja Feb. 19 at 7:27 PM

$CHRS Looking,

1 · Reply

Jack_Nicholson_Truth Feb. 19 at 7:16 PM

$CHRS yes but CASDO results will take two years to mature. Also not clear how p2 data could be used to skip a P3. Will research more

1 · Reply

Cowpokecaleb Feb. 19 at 7:10 PM

$CHRS back in the green by 2% - get the BMW dealership on the line!

1 · Reply

Microcap777 Feb. 19 at 6:53 PM

$CHRS Standing TALL.

0 · Reply

Moneyaintfree Feb. 19 at 3:29 PM

$CHRS holding strong. Let’s get the readouts and go up

0 · Reply

neofeudal Feb. 19 at 3:17 PM

$CHRS I only say $6 so you don’t mock me for saying $20.

0 · Reply

simonig1 Feb. 19 at 3:15 PM

$CHRS How Recent Developments Are Rewriting The Story For Coherus Oncology (CHRS) Link: https://finance.yahoo.com/news/recent-developments-rewriting-story-coherus-141119100.html

0 · Reply

cdlawton07 Feb. 19 at 2:30 PM

$CHRS Building off my last post, that was in reference to the casdozo/tori trial. It changes the game for us if FDA will allow our current phase 2 trial to be our pivotal. All they have to do is replicate the data from Casdozo phase 1 and it could be ready for FDA submittal by end of 2026. With a total addressable market of $4 billion in 1L HCC, that would drastically change our market cap. One of the casdozo trial leaders said that if it gets approved, there is no doubt in his mind that it would become THEE standard treatment for HCC based on the results he is seeing.

1 · Reply

cdlawton07 Feb. 19 at 2:17 PM

$CHRS the article about FDA only requiring a single trial could be huge news for us. Bouncing ideas off Gemini, it says that the sweet spot for the trials FDA will be willing approve on a single trial have on average 70-100 patients. From Gemini "If Coherus can maintain that ~10% "delta" (improvement) over the control group in these 72 patients, the new FDA rules essentially allow them to use this "Phase 2" as their Pivotal Trial."

0 · Reply

Market Cap	90.31M
Revenue (ttm)	266.96M
Net Income (ttm)	28.51M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	10.68%
Debt to Equity Ratio	-0.20

Volume	1,822,400
Avg Vol	1,708,078
Day's Range	N/A - N/A
Shares Out	115.93M
Stochastic %K	30%
Beta	1.01
Analysts	Strong Sell
Price Target	$5.26